Lista de obras - Alessio Cortellini - Dominio Público Uruguay

"Palliative" or "Supportive": Is It Just a Matter of Word?

artículo científico publicado en 2018

"Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer.

artículo científico publicado en 2018

A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

scientific article published in 2022

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

artículo científico publicado en 2019

A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients

artículo científico publicado en 2020

A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients

scientific article published on 01 August 2019

An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival

artículo científico publicado en 2020

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-r

scientific article published on 04 February 2020

Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study

artículo científico publicado en 2020

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm

artículo científico publicado en 2020

Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

artículo científico publicado en 2020

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

scientific article published on 01 October 2020

COVID-19 Pneumonia and Immune-Related Pneumonitis: critical issues on differential diagnosis, potential interactions and management

artículo científico publicado en 2020

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

artículo científico publicado en 2020

Cancer Care After Natural Disaster: Different Countries, Similar Problems

scientific article published on 01 July 2019

Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study

artículo científico publicado en 2020

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

scientific article published on 22 February 2019

Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer

artículo científico publicado en 2019

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50

artículo científico publicado en 2020

Combined PD-1/VEGFR blockade: a new era of treatment for hepatocellular cancer

artículo científico publicado en 2020

Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study

artículo científico publicado en 2020

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

scientific article published on 21 February 2019

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

scientific article published on 15 November 2019

Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment

scientific article published on 17 March 2020

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

artículo científico publicado en 2020

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study

artículo científico publicado en 2020

Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer

scientific article published on 30 August 2020

Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study

scientific article published on 16 May 2020

Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer

scientific article published on 06 April 2020

Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study

artículo científico publicado en 2020

Family history of cancer and DNA damage response genes: Two sides of the same coin?

scientific article published on 08 December 2018

Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study

artículo científico publicado en 2018

First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience

scientific article published on 30 April 2019

Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series

scientific article published on 24 March 2020

Home care for cancer patients during COVID-19 pandemic: the "double triage" protocol

scientific article published on 30 March 2020

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study

Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab

scientific article published on 01 December 2018

Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma

artículo científico publicado en 2019

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

artículo científico publicado en 2020

Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients

artículo científico publicado en 2020

Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts.

artículo científico publicado en 2017

Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study

artículo científico publicado en 2020

Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study

artículo científico publicado en 2019

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

artículo científico publicado en 2020

Into the storms: Organising oncological home care services during natural disasters and global pandemics

artículo científico publicado en 2021

Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases

scientific article published on 23 January 2020

KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease.

artículo científico publicado en 2018

Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study

artículo científico publicado en 2020

Letter to the Editor: considerations about recent findings on long-term adverse events of PD-1/PD-L1 checkpoint inhibitors

scientific article published on 19 September 2020

Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation

artículo científico publicado en 2019

Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice.

artículo científico publicado en 2017

Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges

artículo científico publicado en 2019

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes

artículo científico publicado en 2019

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

artículo científico publicado en 2022

Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study

scientific article published on 13 December 2019

Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma

artículo científico publicado en 2020

Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report

scientific article published on 02 January 2019

Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: The PRIME-HCC trial.

artículo científico publicado en 2022

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study ⬇️

artículo científico

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

artículo científico publicado en 2020

Rare bone toxicity associated with vismodegib

artículo científico publicado en 2020

Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma

artículo científico publicado en 2021

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome.

artículo científico publicado en 2018

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis

scientific article published on 10 February 2019

Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy

scientific article published on 27 September 2018

Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer

scientific article published on 25 February 2020

Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience

artículo científico publicado en 2020

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG

artículo científico publicado en 2020

TERAVOLT: Thoracic Cancers International COVID-19 Collaboration

scientific article published on 16 May 2020

The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy

artículo científico publicado en 2020

The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial

scientific article published on 20 April 2020

The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study

scientific article published on 24 May 2018

The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings

scientific article published on 01 February 2020

The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice

scientific article published on 10 October 2018

The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference

scientific article published on 07 May 2020

The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a "transcriptomic compass"?

artículo científico publicado en 2019

Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen

artículo científico publicado en 2018

Topical Menthol for Treatment of Chemotherapy-induced Peripheral Neuropathy.

artículo científico publicado en 2017

Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1

artículo científico publicado en 2020

Unlocking the secret of the obesity paradox in renal tumours

artículo científico publicado en 2019

Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer

Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

artículo científico publicado en 2019

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice

scientific article published on 25 March 2019

Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study

scientific article published on 29 January 2020

Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study

scientific article published on 06 July 2019

What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudes

scientific article published on 01 May 2019

Where are we with treatment options after first line in small cell lung cancer?-report of two opposite cases treated with CAPTEM regimen and possible perspectives.

artículo científico publicado en 2018

[The CoViD-19 epidemic is posing entirely new problems for home cancer care services.]

scientific article published on 01 April 2020

Lista de obras de Alessio Cortellini

"Palliative" or "Supportive": Is It Just a Matter of Word?

"Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer.

A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients

A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients

An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-r

Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm

Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

COVID-19 Pneumonia and Immune-Related Pneumonitis: critical issues on differential diagnosis, potential interactions and management

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Cancer Care After Natural Disaster: Different Countries, Similar Problems

Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50

Combined PD-1/VEGFR blockade: a new era of treatment for hepatocellular cancer

Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study

Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer

Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study

Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer

Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study

Family history of cancer and DNA damage response genes: Two sides of the same coin?

Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study

First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience

Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series

Home care for cancer patients during COVID-19 pandemic: the "double triage" protocol

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study

Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab

Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Immunological insights on influenza infection and vaccination during immune checkpoint blockade in cancer patients

Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts.

Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study

Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Into the storms: Organising oncological home care services during natural disasters and global pandemics

Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases

KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease.

Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study

Letter to the Editor: considerations about recent findings on long-term adverse events of PD-1/PD-L1 checkpoint inhibitors

Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation

Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice.

Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study

Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma

Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report

Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: The PRIME-HCC trial.

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study ⬇️

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

Rare bone toxicity associated with vismodegib

Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome.

Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis

Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy

Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer

Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG

TERAVOLT: Thoracic Cancers International COVID-19 Collaboration

The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy

The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial

The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study

The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings

The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice

The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference

The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a "transcriptomic compass"?

Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen

Topical Menthol for Treatment of Chemotherapy-induced Peripheral Neuropathy.

Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1